Cookie Settings
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Other cookies are those that are being identified and have not been classified into any category as yet.

ENUSAU
Close Close Nav Takeover

NHS Wales

Mass vaccination programme

NHS Wales – Mass Vaccination Programme – Acceleration
Client Cardiff and Vale University Health Board NHS Wales
Region UK
Sector Public Sector, Health and Not For Profit
Offering Organisation Change & Implementation

The Challenge

Cardiff and Vale University Health Board (CAV) needed to rapidly increase the capacity of its Mass Vaccination Programme (MVP) while maintaining flexibility to respond to an unpredictable vaccine supply. In a complex environment involving multiple organisations, Q5 were asked to lead the process to develop options for accelerating the MVP and support the swift implementation of the chosen solution.

Our Approach

Q5 quickly stood up a team in response to the challenge, forming an integrated team across Q5, CAV, and local government bodies Cardiff Council and Vale of Glamorgan Council. The team led a 14-day rapid sprint to ideate, evaluate, and shortlist options for accelerating the pace of the vaccination programme, to be taken forward to implementation by the Health Board.​​

The sprint provided both focused outcomes that provided incremental improvements to existing processes, patient flow, and capacity within the MVP as well as radical options for significant vaccination acceleration.​​

Our approach to the sprint included: 

  • Conducting research on international best practice, forging mutually beneficial relationships with healthcare providers leading vaccination rollouts in the US, Israel, and England, and applying their learnings to the programme in Wales.
  • Creating a data model to support programme decision making, simulating delivery scenarios and their impact on the completion of the programme.
  • Creating a PMO team that underpinned the entire project, providing central coordination of risks and interdependencies, and driving fast-paced activity across all workstreams. 
  • Leading the development of the acceleration programme’s key deliverables, including Executive reports and options proposals to senior local and national government leaders – setting out a number of innovative options to increase capacity at pace.
  • Supporting patient and clinical flow design within the existing Mass Vaccination Centre, increasing space utilisation efficiency by 20% on previous designs.

Key Outcomes

  • The main outcome of the sprint was the successful, on-time launch of Wales’ largest vaccination centre (the chosen option for acceleration), providing the Health Board with the capacity and flexibility to expand the vaccination programme and respond flexibly to a rapidly shifting vaccine supply.
  • CAV’s vaccination capacity increased by 150% to over 10k vaccinations per day, ensuring that the rollout was only constrained by vaccine supply levels.
  • The collaborative approach between Q5, CAV and local government was celebrated as a major success for partnership working across public and private sectors.
  • The Q5-developed data model ensured that decisions were taken in full view of the effect they would have on the speed of the vaccine rollout.
  • The rhythm, governance and innovative ways of working developed by the PMO team were viewed as instrumental to the programme’s success. As a result, Q5 were asked to continue our support of the Mass Vaccination Programme towards its completion.​ ​
Case studies

Discover more client stories

Get in touch with our experts